Caribou Biosciences shuts down after failing to fund late-stage CAR-T lymphoma trial

Caribou Biosciences, a biotech co-founded by Nobel laureate Jennifer Doudna, announced it is shutting down.

The closure follows the company's inability to raise the funding required for a Phase 3 trial of its off-the-shelf CAR-T therapy, vespa-cel, aimed at advanced B-cell non-Hodgkin lymphoma.

As a result, Caribou will discontinue development of both of its CRISPR-based CAR-T candidates, highlighting the financing challenges faced by biotech firms pursuing late-stage trials.